Avalo Therapeutics Inc. (AVTX)
NASDAQ: AVTX
· Real-Time Price · USD
11.60
1.44 (14.17%)
At close: Sep 05, 2025, 3:59 PM
12.57
8.36%
After-hours: Sep 05, 2025, 07:45 PM EDT
14.17% (1D)
| Bid | 10 |
| Market Cap | 152.57M |
| Revenue (ttm) | 441K |
| Net Income (ttm) | -46.22M |
| EPS (ttm) | 6.54 |
| PE Ratio (ttm) | 1.77 |
| Forward PE | -1.62 |
| Analyst | Buy |
| Ask | 12.59 |
| Volume | 360,701 |
| Avg. Volume (20D) | 193,695 |
| Open | 10.85 |
| Previous Close | 10.16 |
| Day's Range | 10.85 - 12.41 |
| 52-Week Range | 3.39 - 16.00 |
| Beta | 0.89 |
About AVTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AVTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AVTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
+11.93%
Avalo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
2 weeks ago · seekingalpha.com
Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS ResultsAvalo Therapeutics' value mostly hinges on AVTX-009. This is an IL-1β mAb in a Phase 2 LOTUS trial for hidradenitis suppurativa. This Phase 2 trial should give us topline results by mid-2026, which I ...